Den Europæiske Union - dansk - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vacciner - profylakse af influenza forårsaget af a (h1n1) v 2009 virus. celvapan bør anvendes i overensstemmelse med officielle retningslinjer.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

nanotherapeutics bohumil s.r.o. - influenzavirus a/california/7/2009 (h1n1)v-lign. stamme, inaktiverede split virioner, influenzavirus a/perth/16/2009 (h3n2) lignende stamme (a/victoria/210/2009 nymc x-187 reassortant), influenzavirus b/brisbane/60/2008, split virioner, inaktiveret - injektionsvæske, suspension, fyldt injektionssprøjte - 15 mikrogram

Den Europæiske Union - dansk - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - dexamethason - macular edema; uveitis - ophthalmologicals, other ophthalmologicals - ozurdex er indiceret til behandling af voksne patienter med macula ødem efter enten gren retinal-vene okklusion (brvo) eller central retinal-vene okklusion (crvo). ozurdex er indiceret til behandling af voksne patienter med betændelse i den bageste del af øjet viser sig som ikke-smittefarlige uveitis. ozurdex er indiceret til behandling af voksne patienter med synsnedsættelse på grund af diabetisk macula ødem (dme), som er pseudophakic, eller som anses for tilstrækkeligt lydhøre over for, eller uegnet til ikke-kortikosteroidbehandling.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited  - voretigene neparvovec - leber congenital amaurosis; retinitis pigmentosa - other ophthalmologicals - luxturna er indiceret til behandling af voksne og pædiatriske patienter med tab af synet på grund af arvelig retinal dystrofi skyldes bekræftet biallelic rpe65 mutationer, og som har tilstrækkelig levedygtige celler retinal.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anæmi, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocytopenisk, idiopatisk - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 og 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 og 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukæmi, lymfocytisk, kronisk, b-celle - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

nordic group b.v. - tegafur, gimeracil, oteracil - mave neoplasmer - antineoplastiske midler - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Danmark - dansk - SEGES Landbrug & Fødevarer

belchim crop protection nv/sa - pyridat - vanddispergerbart pulver - 450 g/kg pyridat